Management of ICI Immunotherapy-Related Adverse Events:

The KMCC SACT Governance Group have reviewed the ESMO management of toxicities from ICI immunotherapy - clinical practice guideline for diagnosis, treatment and follow-up, and have agreed to adopt these for use within KMCC.

Management of toxicities from ICI immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Supplementary Data: Checkpoint Inhibitor Monitoring Guidance